Benedict Financial Advisors Inc. Invests $35,000 in Gain Therapeutics, Inc. (NASDAQ:GANX)

Benedict Financial Advisors Inc. acquired a new stake in Gain Therapeutics, Inc. (NASDAQ:GANX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,000 shares of the company’s stock, valued at approximately $35,000. Benedict Financial Advisors Inc. owned about 0.06% of Gain Therapeutics at the end of the most recent quarter.

Separately, Renaissance Technologies LLC boosted its stake in Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Stock Performance

GANX stock opened at $2.61 on Friday. The stock has a 50-day moving average price of $2.03 and a two-hundred day moving average price of $1.80. Gain Therapeutics, Inc. has a 1 year low of $0.89 and a 1 year high of $5.30. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Wall Street Analysts Forecast Growth

GANX has been the topic of several analyst reports. Roth Mkm reiterated a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a report on Tuesday, December 24th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $7.25.

Gain Therapeutics Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.